Embera NeuroTherapeutics is a development stage pharmaceutical company focused on developing treatments for smoking cessation and other addictions, for which there are a limited range of effective drug therapies or have no approved treatments. Embera is developing a novel addiction treatment (EMB-001) that targets specific and complementary brainfunctions that drive the craving and relapse associated with these disorders, an approach based on breakthrough discoveries of the scientific founder.

Biotechnology

Therapeutics

Embera NeuroTherapeutics

Bob Linke

Ross Barrett

Lawrence Yarmaloff

Ann Robbins

Julie Ann Straub

Gary Connor

Bruce McCarthy

The Leadership Team at Embera NeuroTherapeutics is responsible for guiding the company's strategic direction, overseeing the development of novel addiction treatments, and ensuring regulatory compliance and clinical success. Their collective expertise drives the critical phases of research, development, and commercialization of EMB-001, aimed at addressing the unmet needs in addiction therapies.

Leadership Team

Advisory and Science Team

Leadership Team

About

Team members

Other teams at Embera NeuroTherapeutics

Advisory and Science Team